Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

BioMark Diagnostics Secures Global IP for Metabolomics Lung Cancer Test, Eyes 2026 Commercial Launch Amid Tight Cash Position

By The Northwire Desk — AI Analysis Jun 23, 2026 · 08:31 BUX · 0.55 BioMark Diagnostics Inc.
Executive Summary
  • BioMark Diagnostics announced formal patent allowances from the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its proprietary metabolomics-based blood test targeting non-small cell lung cancer (NSCLC).
  • The allowances protect the core metabolic signatures and advanced algorithms powering the minimally invasive screening panel.
  • The company is advancing parallel patent applications in the United States, China, and Japan.
  • Commercial launch of the screening panel is targeted for later in 2026.
  • Clinical validation is anchored in over 15,000 blood samples collected across clinical sites in Quebec, France, and Germany.
  • This follows a USPTO patent allowance announced on June 9, 2026, for a urine-based detection method, expanding the platform beyond blood matrices.
Material Impact
  • The patent allowances secure the intellectual property foundation required for commercialization, international partnerships, and potential licensing agreements.
  • This is a standard regulatory and IP milestone for a pre-revenue diagnostics company advancing a novel liquid biopsy platform.
  • No immediate revenue, pricing, reimbursement strategy, or partnership terms are disclosed in the release.
  • The news confirms the company's stated roadmap without introducing unexpected financial or operational shifts.
BUX · Price
Company Overview
  • BioMark Diagnostics is developing a minimally invasive, metabolomics-based liquid biopsy platform for early-stage lung cancer detection.
  • The technology uses clinical mass spectrometry and AI/ML to identify biochemical tumor changes in blood and urine, aiming to detect cancer earlier than traditional ctDNA tests that rely on fragmented DNA.
  • The company is targeting the global liquid biopsy market, projected to exceed $24 billion by 2035, with specific focus on North America, Europe, and Asia.
  • Strategic focus includes expanding into non-invasive matrices (urine), securing global IP, and pursuing decentralized, home-based screening models to address geographic and infrastructure barriers.
Read the original news release →

More from BioMark Diagnostics Inc.

Jun 09, 2026 · 08:31

Metabolomics-driven liquid biopsy platform expands from blood to urine, securing US IP while navigating a tight pre-revenue balance sheet.

Other Apr 14, 2026 · 08:31

BioMark Diagnostics

Production / Operations Jan 15, 2026 · 19:14

Biomark research to be published in Frontiers

Other Jan 15, 2026 · 08:32

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Other Dec 31, 2025 · 08:31

BioMark: 2025 Achievements & 2026 Vision

Production / Operations